ABC-101 demonstrates superior efficacy in preclinical colorectal cancer models compared to standard of care.
New Cases /Year Worldwide
of patients will have a metastatic form
80 000 new cases /year US + EU
In 3rd line for all patients’ refractory or relapsing in combination to irinotecan
Superior penetration in mucosal tissues with selective CEA recognition
Engage monocytes, macrophages and granulocytes via CD89 receptor and T reg via FCLR3 receptor.
Induce tumor growth inhibition & apoptosis
Abcely is shaping a pipeline designed to unlock new therapeutic and market opportunities.
The announcement of a cancer diagnosis is a tsunami that stops a life in its tracks, leaving indelible scars and even shattering it completely. Treatment offers repair and reconstruction, healing the body and restoring its integrity. Treatment through remission and healing gives a second chance at life, which takes on an enhanced, unprecedented and new value that every patient feels after being so afraid of losing it.
The ABCELY logo was inspired by the Japanese tradition of ceramic repair, which, instead of hiding fractures and scars, sublimates them by highlighting them in gold, creating a work of art of immense value while restoring its original functionality. Life is never the same after such an experience, both in body and soul. With humility, our logo seeks to symbolize a life rebuilt and sublimated after such a devastating illness.
